Hair Relaxer Cancer Lawsuits

Endocrine-Disrupting Chemicals: The Mechanism of Harm

Chemical hair relaxers contain multiple classes of endocrine-disrupting chemicals that interfere with the body's hormonal system. Phthalates (particularly DEP and DEHP) are plasticizers used in fragrances that mimic estrogen and promote inflammation. Parabens (methylparaben, ethylparaben, butylparaben) are preservatives with estrogenic activity — studies have found elevated paraben levels in women with endometrial cancer. Formaldehyde and formaldehyde-releasing agents are potent carcinogens that form DNA adducts, causing genomic instability. Cyclosiloxanes (D4, D5) are silicone compounds with endocrine-disrupting properties; D4 is a suspected carcinogen.

The scalp absorption pathway is critical to understanding the harm. Chemical relaxers work by breaking disulfide bonds in hair protein using strong alkaline agents (sodium hydroxide or calcium hydroxide). These same agents chemically compromise the scalp's protective barrier, dramatically increasing percutaneous absorption of the EDCs in the product. Women who experience scalp burning or irritation during application — a nearly universal experience — are absorbing even higher concentrations of these chemicals.

The Scientific Evidence Beyond the Sister Study

The NIEHS Sister Study (Chang et al., JNCI 2022) was the catalyst, but it was not the only evidence. A 2021 study from the same Sister Study cohort (White et al., Carcinogenesis) found that frequent straightener use was associated with a 2.19x increased risk of ovarian cancer. The Black Women's Health Study (Bertrand et al., Environmental Research 2023) — conducted entirely within a cohort of 44,798 Black women — found that long-term relaxer use (>5 years) was associated with a >50% increased risk of uterine cancer in postmenopausal women.

A 2018 chemical testing study (James-Todd et al., Environmental Research) analyzed hair products and found 45 endocrine-disrupting or asthma-associated chemicals across 10 chemical classes — with 84% of detected chemicals NOT disclosed on product labels. This labeling gap is central to the failure-to-warn claims.

The Product Labeling Failure

Unlike pharmaceutical products that undergo rigorous FDA pre-market review, cosmetic products historically required no pre-market safety testing or approval. Manufacturers self-certified safety. The Modernization of Cosmetics Regulation Act (MoCRA), signed in December 2022, expanded FDA authority over cosmetics but regulations are still being implemented. The FDA proposed banning formaldehyde from hair straighteners in October 2023 but has repeatedly missed its own deadlines for finalizing the rule.

The failure-to-warn case is strengthened by testing data showing that 84% of EDCs found in hair relaxers were not listed on product labels. Consumers had no way to know what chemicals they were absorbing through their scalps. Products marketed to children ("Just for Me") contained the same unlabeled EDCs, raising particular concerns about early-life endocrine disruption.

Disproportionate Marketing to Black Women

The racial justice dimension of this case is not incidental — it is central to the liability theory. Defendants aggressively marketed hair relaxers to Black women and girls through decades of advertising in Black-owned media (Ebony, Jet, Essence, BET). Product names ("Dark & Lovely," "African Pride," "Just for Me") explicitly targeted Black consumers. The products were positioned as necessities for professional acceptability in a society that discriminated against natural Black hair.

This marketing strategy created a population-specific exposure pathway. Black women use hair relaxers more frequently, begin use at younger ages (often in childhood), and consequently accumulate higher lifetime EDC exposure than any other demographic. The litigation argues that defendants knew who would be most exposed and most harmed — and marketed to them anyway without disclosing cancer risks.

The Bellwether Process and Path to Resolution

The MDL is following a structured path toward bellwether trials. Each side selected 20 potential bellwether cases in April 2025. Case-specific discovery for 32 cases was due by February 2026. The court will narrow to 10 trial cases by spring 2026. Daubert hearings on general causation experts are scheduled for April–June 2026. If plaintiffs' experts survive Daubert challenges, settlement pressure increases dramatically. First trials are expected in mid-2027.

The Daubert hearings represent the most critical near-term milestone. If the court rules that the Sister Study and supporting epidemiological evidence establish general causation, the defendants face enormous exposure across thousands of cancer claims. An adverse Daubert ruling, conversely, could derail the litigation. Filing now positions your case in the pipeline regardless of outcome.